<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21177810</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.</ArticleTitle><Pagination><StartPage>2364</StartPage><EndPage>2372</EndPage><MedlinePgn>2364-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02249-10</ELocationID><Abstract><AbstractText>Enviroxime is an antienterovirus compound that targets viral protein 3A and/or 3AB and suppresses a step in enterovirus replication by unknown mechanism. To date, four antienterovirus compounds, i.e., GW5074, Flt3 inhibitor II, TTP-8307, and AN-12-H5, are known to have similar mutations in the 3A protein-encoding region causing resistance to enviroxime (a G5318A [3A-Ala70Thr] mutation in poliovirus [PV]) and are considered enviroxime-like compounds. Recently, antienterovirus activity of a phosphatidylinositol 4-kinase III beta (PI4KB) inhibitor, PIK93, was reported, suggesting that PI4KB is an important host factor targetable by antienterovirus compounds (N. Y. Hsu et al., Cell 141:799-811, 2010). In this study, we analyzed the inhibitory effects of previously identified enviroxime-like compounds (GW5074 and AN-12-H5) and a newly identified antienterovirus compound, T-00127-HEV1, on phosphoinositide (PI) kinases. We found that T-00127-HEV1 inhibited PI4KB activity with a higher specificity for than other PI kinases, in contrast to GW5074, which had a broad specificity for PI kinases. In contrast, AN-12-H5 showed no inhibitory effect on PI4KB activity and only moderate inhibitory effects on PI 3-kinase activity. Small interfering RNA (siRNA) screening targeting PI kinases identified PI4KB is a target of GW5074 and T-00127-HEV1, but not of AN-12-H5, for anti-PV activity. Interestingly, T-00127-HEV1 and GW5074 did not inhibit hepatitis C virus (HCV) replication, in contrast to a strong inhibitory effect of AN-12-H5. These results suggested that PI4KB is an enterovirus-specific host factor required for the replication process and targeted by some enviroxime-like compounds (T-00127-HEV1 and GW5074) and that enviroxime-like compounds may have targets other than PI kinases for their antiviral effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Minetaro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Tokyo 208-0011, Japan. minetaro@nih.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Hirotatsu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Tetsuo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Okabe</LastName><ForeName>Takayoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wakita</LastName><ForeName>Takaji</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010636">Phenols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.67</RegistryNumber><NameOfSubstance UI="D019870">1-Phosphatidylinositol 4-Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5V34WG2BE</RegistryNumber><NameOfSubstance UI="C021595">viroxime</NameOfSubstance></Chemical><Chemical><RegistryNumber>P0LE4QW0S6</RegistryNumber><NameOfSubstance UI="C489251">5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019870" MajorTopicYN="N">1-Phosphatidylinositol 4-Kinase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21177810</ArticleId><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="doi">10.1128/JVI.02249-10</ArticleId><ArticleId IdType="pii">JVI.02249-10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arita, M., Y. Ami, T. Wakita, and H. Shimizu. 2008. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 82:1787-1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita, M., N. Nagata, T. Sata, T. Miyamura, and H. Shimizu. 2006. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 87:3317-3327.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita, M., Y. Takebe, T. Wakita, and H. Shimizu. 2010. A bifunctional anti-enterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J. Gen. Virol. 91:2734-2744.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita, M., T. Wakita, and H. Shimizu. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90:1869-1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita, M., T. Wakita, and H. Shimizu. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 89:2518-2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain, J., et al. 2007. The selectivity of protein kinase inhibitors; a further update. Biochem. J. 408:297-315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267365</ArticleId><ArticleId IdType="pubmed">17850214</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltera, R. F., Jr., and D. R. Tershak. 1989. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 63:4441-4444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC251066</ArticleId><ArticleId IdType="pubmed">2550675</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton, D. J., and J. B. Flanegan. 1997. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J. Virol. 71:8482-8489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192311</ArticleId><ArticleId IdType="pubmed">9343205</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov, G. A., Q. Feng, K. Nikovics, C. L. Jackson, and E. Ehrenfeld. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4:e1000216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581890</ArticleId><ArticleId IdType="pubmed">19023417</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger, K. L., et al. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678598</ArticleId><ArticleId IdType="pubmed">19376974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienz, K., D. Egger, M. Troxler, and L. Pasamontes. 1990. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J. Virol. 64:1156-1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249229</ArticleId><ArticleId IdType="pubmed">2154600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodian, D. 1949. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 6:563-578.</Citation><ArticleIdList><ArticleId IdType="pubmed">18119382</ArticleId></ArticleIdList></Reference><Reference><Citation>Borawski, J., et al. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83:10058-10074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748049</ArticleId><ArticleId IdType="pubmed">19605471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordeleau, M. E., et al. 2006. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2:213-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532013</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown-Augsburger, P., et al. 1999. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch. Virol. 144:1569-1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">10486111</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliguiri, L. A., and I. Tamm. 1968. Action of guanidine on the replication of poliovirus RNA. Virology 35:408-417.</Citation><ArticleIdList><ArticleId IdType="pubmed">4298649</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett, M. S., J. Neyts, and J. F. Modlin. 2008. A case for developing antiviral drugs against polio. Antiviral Res. 79:179-187.</Citation><ArticleIdList><ArticleId IdType="pubmed">18513807</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication, NRC. 2006. Exploring the role of antiviral drugs in the eradication of polio: workshop report. The National Academies Press, Washington, DC.</Citation></Reference><Reference><Citation>Couderc, T., et al. 1989. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J. Gen. Virol. 70:2907-2918.</Citation><ArticleIdList><ArticleId IdType="pubmed">2555432</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty, S., M. C. Saleh, L. Gitlin, O. Beske, and R. Andino. 2004. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J. Virol. 78:3378-3386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC371039</ArticleId><ArticleId IdType="pubmed">15016860</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuconati, A., A. Molla, and E. Wimmer. 1998. Brefeldin A inhibits cell-free, de novo synthesis of poliovirus. J. Virol. 72:6456-6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109807</ArticleId><ArticleId IdType="pubmed">9658088</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma, A. M., et al. 2008. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J. Virol. 82:4720-4730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2346740</ArticleId><ArticleId IdType="pubmed">18337578</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma, A. M., et al. 2008. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 14:545-551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570929</ArticleId><ArticleId IdType="pubmed">18394270</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma, A. M., et al. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dierssen, U., F. Rehren, C. Henke-Gendo, G. Harste, and A. Heim. 2008. Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay. J. Clin. Virol. 42:58-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164234</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers, H. J., and I. Tamm. 1961. Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole. J. Exp. Med. 113:657-682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137377</ArticleId><ArticleId IdType="pubmed">13725919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox, M. P., M. J. Otto, and M. A. McKinlay. 1986. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30:110-116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC176446</ArticleId><ArticleId IdType="pubmed">3019232</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller, R., M. Vignuzzi, R. Andino, and J. Frydman. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21:195-205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1770902</ArticleId><ArticleId IdType="pubmed">17234885</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz, B. A., and L. M. Vance. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69:4189-4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu, N. Y., et al. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Irurzun, A., L. Perez, and L. Carrasco. 1992. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166-175.</Citation><ArticleIdList><ArticleId IdType="pubmed">1329315</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight, Z. A., et al. 2006. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946820</ArticleId><ArticleId IdType="pubmed">16647110</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Macejak, D. G., and P. Sarnow. 1992. Association of heat shock protein 70 with enterovirus capsid precursor P1 in infected human cells. J. Virol. 66:1520-1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240877</ArticleId><ArticleId IdType="pubmed">1310763</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahboobi, S., et al. 2006. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 49:3101-3115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16722630</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews, D. A., et al. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:11000-11007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynell, L. A., K. Kirkegaard, and M. W. Klymkowsky. 1992. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66:1985-1994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288987</ArticleId><ArticleId IdType="pubmed">1312615</ArticleId></ArticleIdList></Reference><Reference><Citation>Molla, A., C. U. Hellen, and E. Wimmer. 1993. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J. Virol. 67:4688-4695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237854</ArticleId><ArticleId IdType="pubmed">8392608</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick, A. K., et al. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444-2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear, D. C., et al. 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63:2002-2007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250615</ArticleId><ArticleId IdType="pubmed">2539499</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister, T., and E. Wimmer. 1999. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J. Biol. Chem. 274:6992-7001.</Citation><ArticleIdList><ArticleId IdType="pubmed">10066753</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez, P. L., and L. Carrasco. 1992. Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. J. Virol. 66:1971-1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288985</ArticleId><ArticleId IdType="pubmed">1372367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin, A. B. 1965. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194:872-876.</Citation><ArticleIdList><ArticleId IdType="pubmed">5321495</ArticleId></ArticleIdList></Reference><Reference><Citation>Salk, J. E., et al. 1954. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am. J. Public Health Nations Health 44:994-1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1620864</ArticleId><ArticleId IdType="pubmed">13180761</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu, H., et al. 2000. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74:4146-4154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111929</ArticleId><ArticleId IdType="pubmed">10756027</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance, L. M., N. Moscufo, M. Chow, and B. A. Heinz. 1997. Poliovirus 2C region functions during encapsidation of viral RNA. J. Virol. 71:8759-8765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192341</ArticleId><ArticleId IdType="pubmed">9343235</ArticleId></ArticleIdList></Reference><Reference><Citation>Verlinden, Y., A. Cuconati, E. Wimmer, and B. Rombaut. 2000. The antiviral compound 5-(3,4-dichlorophenyl) methylhydantoin inhibits the post-synthetic cleavages and the assembly of poliovirus in a cell-free system. Antiviral Res. 48:61-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918402</ArticleId><ArticleId IdType="pubmed">15951748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, A. Z., I. Mayr, and W. Bode. 1988. The refined 2.3 A crystal structure of human leukocyte elastase in a complex with a valine chloromethyl ketone inhibitor. FEBS Lett. 234:367-373.</Citation><ArticleIdList><ArticleId IdType="pubmed">3391280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikel, J. H., et al. 1980. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J. Med. Chem. 23:368-372.</Citation><ArticleIdList><ArticleId IdType="pubmed">6247489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>